Incorporating some potential obstacles arising from recent Chinese developments
15/09/23 -"Despite Philips gaining confidence, thanks to promising testing results for respiratory devices, improving operations and a big new investor coming on board, our target price resets lower due to ..."
Pages
63
Language
English
Published on
15/09/23
You may also be interested by these reports :
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...
03/06/26
Despite a reduction in our target price, as discussed in the EPS section, our positive recommendation on Qiagen remains unchanged. This optimism is ...
29/05/26
Elekta’s Q4 results revealed an adjusted EBIT exceeding expectations, although sales fell short. The company offered qualitative guidance for ...
26/05/26
Piling up assets is no strategy